Biocomposites signs agreement with Zimmer Biomet to distribute new genex Bone Graft Substitute

genex Bone Graft Substitute upgraded with a new closed-mixing system and a comprehensive set of delivery options for U.S. marketZimmer Biomet will exclusively distribute genex Bone Graft Substitute in the U.S.

Keele, UK, 22 March 2022 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for regenerating bone and managing infection in bone and soft tissue, today announces that it has entered into a multiyear agreement with Zimmer Biomet (NYSE and SIX: ZBH), a global medical technology leader, to exclusively distribute genex Bone Graft Substitute with its new mixing system and delivery options in the U.S. orthopaedic market.

Read more…

© Optimum Strategic Communications.